MetaCap

Cellectis S.A. (CLLS) vs NeOnc Technologies (NTHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeOnc Technologies (NTHI) has outperformed Cellectis S.A. (CLLS) over the past year, losing 46.2% versus a loss of 80.4%. Cellectis S.A. is the larger company by market cap ($92.8 million vs $90.9 million), about 1.0 times the size. Cellectis S.A. converts more of its revenue into profit, with a net margin of -92.7% versus -155404.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLLS-80.36%NTHI-46.25%
+92%+2%-89%
Nov 21, 20251 yearNov 20, 2026
CLLS-27.49%NTHI-80.97%
+318%+108%-103%
Mar 24, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLLS versus NTHI key metrics
MetricCLLSNTHI
Share price$0.9209$3.15
Market cap$92.76M$90.88M
1-day change-7.89%-9.48%
YTD return-80.97%-61.91%
1-year return-80.36%-46.25%
5-year return-89.40%—
EPS (TTM)$-1.26$-1.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.95M$39.99K
Revenue growth (YoY)+75.76%-51.82%
Net income (latest FY)$-67.59M$-62.15M
Gross margin100.00%—
Operating margin-45.34%-145637.52%
Net margin-92.66%-155404.38%
52-week high$5.45$11.38
52-week low$0.881$2.50
Distance from 52-week high-83.10%-72.31%
Analyst consensusbuystrong_buy
Avg. price target upside+497.24%+439.68%
Average volume115.00K187.23K
Shares outstanding72.73M28.85M
Employees2245
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NTHI has outperformed CLLS by 34.1 percentage points over the past year.
  • Cellectis S.A. is more profitable, keeping -92.7 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
  • Cellectis S.A. grew revenue faster in its latest fiscal year (+75.76% vs -51.82%).

About Cellectis S.A.

CLLS stock →

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).

Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees

About NeOnc Technologies

NTHI stock →

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CLLS vs NTHI FAQ

Which is bigger, Cellectis S.A. or NeOnc Technologies?

Cellectis S.A. (CLLS) is larger, with a market capitalization of $92.76M compared with $90.88M for NeOnc Technologies (NTHI).

Which stock has performed better over the past year, CLLS or NTHI?

NTHI returned -46.25% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.

Are Cellectis S.A. and NeOnc Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons